Our results indicate that the [18F]-labeled compound [18F]DCFPyL is a highly promising alternative to [68Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.